DNLI
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Denali Therapeutics entered an agreement to sell a rare pediatric disease priority review voucher for $195 millionJun 18, 2026
- Biogen and Denali provide update on Phase 2b LUMA study of BIIB122 in early Parkinson’s diseaseMay 23, 2026
- Denali Therapeutics received FDA approval for AVLAYAH to treat Hunter syndromeMar 26, 2026
- Denali Therapeutics announces FDA acceptance and priority review of BLA for Tividenofusp Alfa in Hunter syndrome (MPS II)Jul 10, 2025